{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:39:18Z","timestamp":1790167158144,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.eururo.2022.06.017","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T08:21:45Z","timestamp":1657786905000},"page":"613-622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma"],"prefix":"10.1016","volume":"82","author":[{"given":"Muhammad","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12 Suppl","key":"10.1016\/j.eururo.2022.06.017_b0005","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E","article-title":"Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts","volume":"80","author":"Ning","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.06.017_b0010","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1082504","article-title":"Tumor response to radiotherapy regulated by endothelial cell apoptosis","volume":"300","author":"Garcia-Barros","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.eururo.2022.06.017_b0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1475-2867-10-40","article-title":"\u03b1-TEA-induced death receptor dependent apoptosis involves activation of acid sphingomyelinase and elevated ceramide-enriched cell surface membranes","volume":"10","author":"Li","year":"2010","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.eururo.2022.06.017_b0020","doi-asserted-by":"crossref","first-page":"23721","DOI":"10.1073\/pnas.2001933117","article-title":"Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients","volume":"117","author":"Chow","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2022.06.017_b0025","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2022.06.017_b0030","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0035","doi-asserted-by":"crossref","first-page":"e905","DOI":"10.1002\/onco.13736","article-title":"Temporal trends and predictors in the use of stereotactic body radiotherapy for treatment of metastatic renal cell carcinoma in the U.S","volume":"26","author":"Paciotti","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2022.06.017_b0040","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0045","unstructured":"European Association of Urology (EAU) Guidelines. Renal cell carcinoma. Renal cell carcinoma - Introduction - Uroweb."},{"key":"10.1016\/j.eururo.2022.06.017_b0050","unstructured":"National Comprehensive Cancer Network. Kidney cancer (version 2.2022). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf."},{"key":"10.1016\/j.eururo.2022.06.017_b0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1067\/j.cpradiol.2017.05.006","article-title":"Long-term clinical outcomes following radiofrequency and microwave ablation of renal cell carcinoma at a single VA medical center","volume":"47","author":"Abboud","year":"2018","journal-title":"Curr Probl Diagn Radiol"},{"key":"10.1016\/j.eururo.2022.06.017_b0060","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2020.06.014","article-title":"Stereotactic ablative radiotherapy for \u2265T1b primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"108","author":"Siva","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2022.06.017_b0065","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3390\/cancers12102763","article-title":"The role of daily adaptive stereotactic MR-guided radiotherapy for renal cell cancer","volume":"12","author":"Tetar","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2022.06.017_b0070","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.3390\/cancers13133129","article-title":"Stereotactic body radiotherapy for frail patients with primary renal cell carcinoma: preliminary results after 4 years of experience","volume":"13","author":"Grelier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2022.06.017_b0075","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12894-019-0531-z","article-title":"Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function","volume":"19","author":"Senger","year":"2019","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2022.06.017_b0080","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clon.2021.03.002","article-title":"Patient-reported quality of life following stereotactic body radiation therapy for primary kidney cancer\u2014results from a prospective cohort study","volume":"33","author":"Swaminath","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.eururo.2022.06.017_b0085","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2020.10.031","article-title":"Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma","volume":"155","author":"Grubb","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0090","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1186\/s12885-018-4916-2","article-title":"TROG 15.03 phase II clinical trial of focal ablative stereotactic radiosurgery for cancers of the kidney\u2014FASTRACK II","volume":"18","author":"Siva","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2022.06.017_b0095","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon.16.2","article-title":"Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma","volume":"12","author":"Siva","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0100","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.juro.2014.03.111","article-title":"Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort","volume":"192","author":"Haddad","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.06.017_b0105","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ijrobp.2021.01.054","article-title":"Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus-safety lead-in results of a phase 2 trial","volume":"110","author":"Margulis","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2022.06.017_b0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11934-005-0062-x","article-title":"Surveillance following radical or partial nephrectomy for renal cell carcinoma","volume":"6","author":"Lam","year":"2005","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.eururo.2022.06.017_b0115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clgc.2019.02.007","article-title":"Stereotactic radiation therapy for renal cell carcinoma brain metastases in the tyrosine kinase inhibitors era: outcomes of 120 patients","volume":"17","author":"Klausner","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2022.06.017_b0120","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00701-020-04537-w","article-title":"Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery","volume":"163","author":"Stenman","year":"2021","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.eururo.2022.06.017_b0125","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/COC.0000000000000849","article-title":"Outcomes of stereotactic radiosurgery and immunotherapy in renal cell carcinoma patients with brain metastases","volume":"44","author":"Uezono","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0130","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.clgc.2018.11.006","article-title":"Stereotactic radiosurgery for multiple brain metastases from renal-cell carcinoma","volume":"17","author":"Wardak","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2022.06.017_b0135","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.18.02218","article-title":"Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study","volume":"37","author":"Flippot","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0140","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jamaoncol.2021.4544","article-title":"Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma","volume":"7","author":"Hirsch","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0145","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bju.15284","article-title":"Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma","volume":"127","author":"Kroeze","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2022.06.017_b0150","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1016\/j.wneu.2017.10.011","article-title":"Radiosurgery for treatment of renal cell metastases to spine: a systematic review of the literature","volume":"109","author":"Smith","year":"2018","journal-title":"World Neurosurg"},{"key":"10.1016\/j.eururo.2022.06.017_b0155","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijrobp.2020.09.019","article-title":"CCTG SC.24\/TROG 17.06: a randomized phase II\/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases","volume":"108","author":"Sahgal","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2022.06.017_b0160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1227\/NEU.0000000000001780","article-title":"Hybrid therapy (surgery and radiosurgery) for the treatment of renal cell carcinoma spinal metastases","volume":"90","author":"Hussain","year":"2022","journal-title":"Neurosurgery"},{"key":"10.1016\/j.eururo.2022.06.017_b0165","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2022.06.017_b0170","unstructured":"Hannan R, Christensen M, Christie A, Garant A, Robles L, Mannala S, Wang C, Hammers H, Arafat W, Courtney K, Bowman IA, Sher D, Ahn C, Cole S, Choy H, Timmerman R, Brugarolas J. Stereotactic Ablative Radiation for Systemic Therapy Na\u00efve Oligometastatic Kidney Cancer. European Urology Oncology. In Press."},{"key":"10.1016\/j.eururo.2022.06.017_b0175","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0180","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s12094-021-02574-0","article-title":"Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?","volume":"23","author":"Marvaso","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0185","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","article-title":"Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study","volume":"22","author":"Chalkidou","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0190","doi-asserted-by":"crossref","first-page":"607595","DOI":"10.3389\/fonc.2021.607595","article-title":"Survival after combining stereotactic body radiation therapy and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5694\/mja2.12046","article-title":"Radiotherapy and immunotherapy: a synergistic effect in cancer care","volume":"210","author":"Turgeon","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.eururo.2022.06.017_b0200","doi-asserted-by":"crossref","first-page":"e000535","DOI":"10.1136\/esmoopen-2019-000535","article-title":"Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study","volume":"4","author":"Dengina","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.eururo.2022.06.017_b0205","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/COC.0000000000000622","article-title":"Survival outcomes after adding stereotactic body radiotherapy to metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors","volume":"43","author":"He","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0210","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.1158\/1078-0432.CCR-21-2083","article-title":"Outcome and immune correlates of a phase II trial of high-dose interleukin-2 and stereotactic ablative radiotherapy for metastatic renal cell carcinoma","volume":"27","author":"Hannan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.06.017_b0215","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study","volume":"81","author":"Masini","year":"2022","journal-title":"Eur Urol"},{"issue":"6_suppl","key":"10.1016\/j.eururo.2022.06.017_b0220","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/JCO.2020.38.6_suppl.614","article-title":"Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC)","volume":"38","author":"Hammers","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0225","doi-asserted-by":"crossref","first-page":"100161","DOI":"10.1016\/j.ctarc.2019.100161","article-title":"Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: the together retrospective study","volume":"22","author":"Buti","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.eururo.2022.06.017_b0230","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma\u2014the RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.06.017_b0235","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13014-021-01937-9","article-title":"Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma","volume":"16","author":"Liu","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0240","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.06.017_b0245","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2021.12.001","article-title":"Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2022.06.017_b0250","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bju.15541","article-title":"Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation","volume":"129","author":"De","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2022.06.017_b0255","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10585-021-10131-w","article-title":"The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group","volume":"38","author":"Franzese","year":"2021","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.eururo.2022.06.017_b0260","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.21873\/anticanres.14730","article-title":"Stereotactic radiotherapy for the treatment of patients with oligo-progressive metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitor: data from the real world","volume":"40","author":"Gebbia","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2022.06.017_b0265","doi-asserted-by":"crossref","first-page":"100692","DOI":"10.1016\/j.adro.2021.100692","article-title":"Stereotactic ablative radiation therapy for oligoprogressive renal cell carcinoma","volume":"6","author":"Schoenhals","year":"2021","journal-title":"Adv Radiat Oncol"}],"updated-by":[{"DOI":"10.1016\/j.eururo.2022.08.018","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000}}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382202468X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382202468X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T20:11:03Z","timestamp":1708459863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382202468X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S030228382202468X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.06.017","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}